U.S. Markets closed

At US$141, Is It Time To Put Charles River Laboratories International, Inc. (NYSE:CRL) On Your Watch List?

Simply Wall St

Charles River Laboratories International, Inc. (NYSE:CRL), which is in the life sciences business, and is based in United States, received a lot of attention from a substantial price increase on the NYSE over the last few months. With many analysts covering the mid-cap stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. However, could the stock still be trading at a relatively cheap price? Let’s take a look at Charles River Laboratories International’s outlook and value based on the most recent financial data to see if the opportunity still exists.

Check out our latest analysis for Charles River Laboratories International

Is Charles River Laboratories International still cheap?

Charles River Laboratories International appears to be overvalued by 24.39% at the moment, based on my discounted cash flow valuation. The stock is currently priced at US$141 on the market compared to my intrinsic value of $113.35. This means that the opportunity to buy Charles River Laboratories International at a good price has disappeared! If you like the stock, you may want to keep an eye out for a potential price decline in the future. Since Charles River Laboratories International’s share price is quite volatile, this could mean it can sink lower (or rise even further) in the future, giving us another chance to invest. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

Can we expect growth from Charles River Laboratories International?

NYSE:CRL Past and Future Earnings, March 15th 2019

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by 51% over the next couple of years, the future seems bright for Charles River Laboratories International. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What this means for you:

Are you a shareholder? CRL’s optimistic future growth appears to have been factored into the current share price, with shares trading above its fair value. However, this brings up another question – is now the right time to sell? If you believe CRL should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.

Are you a potential investor? If you’ve been keeping tabs on CRL for some time, now may not be the best time to enter into the stock. The price has surpassed its true value, which means there’s no upside from mispricing. However, the positive outlook is encouraging for CRL, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Charles River Laboratories International. You can find everything you need to know about Charles River Laboratories International in the latest infographic research report. If you are no longer interested in Charles River Laboratories International, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.